CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
Roflumilastdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01745848
NCT01745848Phase 4Completed
CompareCT.gov

Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease

University of Pittsburgh·interventional·Posted Dec 10, 2012·Updated Aug 29, 2017

In Brief

A Phase 4 clinical trial evaluating Roflumilast for Chronic Obstructive Pulmonary Disease. Completed, enrolled 26 participants across 1 site.

Detailed Summary

Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease surrogate markers of bone metabolism and early cardiovascular disease in individuals with moderate to severe airflow obstruction and a chronic bronchitis phenotype.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 10, 2012
Enrollment StartFeb 1, 2013
Primary CompletionJun 1, 2016
Study CompletionJun 30, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.6 years ago

Interventions

Roflumilastdrug